Literature DB >> 26903275

Drug permeation and barrier damage in Leishmania-infected mouse skin.

Katrien Van Bocxlaer1, Vanessa Yardley2, Sudaxshina Murdan3, Simon L Croft4.   

Abstract

OBJECTIVES: Pathological disorder can disrupt the barrier integrity of the skin, thereby altering the drug delivery from topical formulations to the target site. Cutaneous leishmaniasis (CL) is an infection of the dermal layers of the skin and manifests as a variety of skin lesions from defined nodular forms to plaques and chronic ulcers. The aim of this work was to characterize the physiology and barrier integrity of the Leishmania-infected BALB/c mouse skin and how they impacted delivery of drugs into the skin.
METHODS: A histological evaluation of the structural differences between uninfected and infected skin was performed using haematoxylin/eosin, elastic Van Gieson and Iba-1 stains. As a CL nodule developed and progressed, the skin pH, hydration and trans-epidermal water loss (TEWL) were recorded. Finally, Franz diffusion cells were used to evaluate the influence of the infection on drug delivery through the skin.
RESULTS: We found: (i) structural changes in both the epidermal and dermal layers due to the ingress of inflammatory cells, as shown by immunohistochemistry; (ii) a significant increase in TEWL; and (iii) significantly higher permeation of the model permeants caffeine and ibuprofen and the antileishmanial drugs buparvaquone and paromomycin, for Leishmania-infected skin compared with uninfected skin. The infection had no measurable influence on skin pH and hydration.
CONCLUSIONS: We report profound changes in the skin barrier physiology, function and permeability to drugs of Leishmania-infected skin.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26903275     DOI: 10.1093/jac/dkw012

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Ali Khamesipour; Mostafa Haji Molla Hoseini; Nariman Mosaffa; Ali Anissian; Amitis Ramezani
Journal:  J Mater Sci Mater Med       Date:  2018-07-28       Impact factor: 3.896

2.  Amine-Linked Flavonoids as Agents Against Cutaneous Leishmaniasis.

Authors:  Chin-Fung Chan; Zhen Liu; Iris L K Wong; Xianliang Zhao; Zaofeng Yang; Jiale Zheng; Marianne M Lee; Michael K Chan; Tak Hang Chan; Larry M C Chow
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

3.  Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Authors:  Katrien Van Bocxlaer; Eric Gaukel; Deirdre Hauser; Seong Hee Park; Sara Schock; Vanessa Yardley; Ryan Randolph; Jacob J Plattner; Tejal Merchant; Simon L Croft; Robert T Jacobs; Stephen A Wring
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  Antileishmanial Agents Co-loaded in Transfersomes with Enhanced Macrophage Uptake and Reduced Toxicity.

Authors:  Fatima Zahid; Sibgha Batool; Fakhar Ud-Din; Zakir Ali; Muhammad Nabi; Salman Khan; Omer Salman; Gul Majid Khan
Journal:  AAPS PharmSciTech       Date:  2022-08-16       Impact factor: 4.026

5.  Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions.

Authors:  Manuela Carvalheiro; Jennifer Vieira; Catarina Faria-Silva; Joana Marto; Sandra Simões
Journal:  Drug Deliv Transl Res       Date:  2021-02-03       Impact factor: 4.617

6.  Effect of topical berberine in murine cutaneous leishmaniasis lesions.

Authors:  Alba Calvo; Esther Moreno; Irati Aldalur; Carmen Sanmartín; Esther Larrea; Elena González-Peñas; Juan Manuel Irache; Socorro Espuelas
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

Review 7.  Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities.

Authors:  Katrien Van Bocxlaer; Simon L Croft
Journal:  RSC Med Chem       Date:  2021-01-07

8.  Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration.

Authors:  Simon L Croft
Journal:  Genome Biol       Date:  2016-03-14       Impact factor: 13.583

9.  Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.

Authors:  Gert-Jan Wijnant; Katrien Van Bocxlaer; Amanda Fortes Francisco; Vanessa Yardley; Andy Harris; Mo Alavijeh; Sudaxshina Murdan; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

10.  Liposomes can both enhance or reduce drugs penetration through the skin.

Authors:  Ma F Peralta; Ma L Guzmán; A P Pérez; G A Apezteguia; Ma L Fórmica; E L Romero; Ma E Olivera; D C Carrer
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.